Egg freezing side effects and risks, by the numbers

The common egg freezing side effects — bloating, headaches, mood swings, breast tenderness and pelvic pressure — are temporary, and they end with the cycle. The serious risks are uncommon: moderate or severe ovarian hyperstimulation syndrome, and retrieval complications reported in roughly 0.4% of procedures. Long-term risks, including cancer, remain unproven and genuinely contested.

Most pages on this subject either list side effects without saying how often they happen, or call egg freezing "very safe" and move on. Below is what the numbers say, who published them, and where the evidence runs out.

The ordinary side effects: what two weeks of stimulation feels like

An egg freezing cycle is roughly ten to fourteen days of injectable hormones that push your ovaries to mature a whole cohort of follicles instead of one. Estrogen climbs far above a natural cycle and the ovaries physically enlarge; nearly everything on the standard side-effect list follows from those two facts.

The usual complaints are bloating and abdominal fullness, breast tenderness, headaches, mood swings, fatigue, nausea, and bruising or stinging at the injection sites. Late in stimulation many women describe a heavy, tender pelvic pressure — enlarged ovaries genuinely take up more room. After retrieval, a few days of cramping and light spotting are expected, as is grogginess from the sedation.

These are not complications. They are the predictable pharmacology of the drugs, and they resolve as hormone levels fall. What no published dataset can tell you is how intense yours will be, which is exactly why the Reddit threads on egg freezing side effects range from "barely noticed it" to "I could not button my jeans by day nine." Both are normal. Neither predicts the other. If you want the day-by-day version of what triggers each of these, see our step-by-step walkthrough of the process.

Does freezing eggs stop your periods?

No. Egg freezing does not stop your periods or push you toward menopause. The cycle is disrupted for a few weeks — that is the point of the medication — but a bleed follows it. The RCOG's OHSS guideline describes recovery in non-pregnant patients as usually complete "by the time of the withdrawal bleed," which is the expected end of a freezing cycle since no embryo transfer takes place. That first period after retrieval is often heavier, later, or crampier than your baseline. Cycles typically settle back over the following month or two.

Ovarian hyperstimulation syndrome: the real number, not the scary one

OHSS is the one genuine risk unique to ovarian stimulation. The ovaries over-respond, proinflammatory mediators drive fluid out of the bloodstream and into the abdomen, and in severe cases the RCOG notes women lose the equivalent of about 20% of their calculated blood volume into that third space.

Incidence depends on which severity you mean, and the sources are not fully aligned:

• Mild OHSS — around one-third of conventional IVF cycles (RCOG Green-top Guideline No. 5, 2016; the HFEA quotes the same figure). Managed at home with fluids and pain relief.
• Moderate or severe combined — 3.1% to 8% of conventional IVF cycles per the RCOG guideline; the American figure it cites for 2011 was 1.1%. A 2023 systematic umbrella review in Reproductive Biology and Endocrinology puts moderate-to-severe OHSS at approximately 1–5% of IVF cycles, rising to as high as 20% in high-risk patients.
• Severe enough to need hospital — the 14th European IVF-Monitoring report, covering 25 countries, found OHSS hospitalization in 0.3% of cycles in 2010. In the UK, HFEA-licensed clinics reported 67 severe and critical OHSS incidents across all treatment in 2024/25; mild and moderate cases are not reportable, so that count is a floor, not a total.
• Death — the RCOG states plainly that the precise mortality risk is unknown because there is no international reporting obligation. Its own examples: three deaths in the Netherlands across an estimated 100,000 IVF cycles between 1984 and 2008; zero deaths among 209 severe or critical cases from 73,492 Israeli cycles; and no UK maternal deaths attributed to OHSS in 2006–08, a period covering roughly 119,000 IVF and ICSI cycles.

Why an egg freezing cycle is not an average IVF cycle

Every figure above comes from IVF cohorts, and applying them straight to egg freezing overstates your risk. The RCOG divides OHSS into early onset, within about seven days of the trigger injection, and late onset, ten or more days out, which "is usually the result of endogenous hCG derived from an early pregnancy" — and late OHSS "tends to be more prolonged and severe than the early form."

An egg freezing cycle ends at retrieval. There is no transfer, no pregnancy, and therefore no source of endogenous hCG to trigger the worse half of that split. On top of that, modern freeze-all cycles can use a GnRH agonist trigger instead of hCG. In Bodri and colleagues' series of 4,052 donor retrievals (Reproductive BioMedicine Online, 2008), moderate or severe OHSS occurred in 0.87% of hCG-triggered cycles and in none of the agonist-triggered ones. The RCOG also records meta-analytic evidence that antagonist protocols carry lower OHSS risk than agonist protocols.

Your risk rises if you have PCOS, a high antral follicle count, high AMH, or a previous episode of OHSS — the RCOG names all four. Those are also the profiles that yield the most eggs, which is the uncomfortable trade at the center of this decision. If PCOS or endometriosis is part of your picture, we cover the specifics on how egg freezing works and in the clinic questions below.

Egg retrieval risks: bleeding, infection, torsion

The retrieval is a needle passed through the vaginal wall into each ovary under sedation, typically 15 to 20 minutes. Two large series bound the risk. Levi-Setti and colleagues reviewed 23,827 consecutive retrievals (Fertility and Sterility, 2018): complications in 0.4% per retrieval, hospital admission in 0.29%, surgical intervention in 0.1%. Bodri's 4,052-cycle donor series found complications in 0.42% — 14 intra-abdominal bleeds, two cases of severe pain, one ovarian torsion — with no pelvic infections, no injury to pelvic structures and no anesthetic complications recorded.

One Levi-Setti finding deserves its own sentence, because it is the only risk factor here you can influence by choosing well: complications were significantly associated with operator inexperience, defined as fewer than 250 prior procedures, alongside patient age, BMI, oocyte number and procedure duration. Volume is a safety variable, and it belongs on your list of questions to ask an egg freezing clinic.

Egg freezing and cancer risk: contested, not settled

This is where honest reporting matters most, and where most clinic pages simply write "no link has been found." ASRM's 2024 guideline Fertility drugs and cancer is more careful than that. On breast cancer it concludes women "should be informed that there does not appear to be an increased risk of breast cancer associated with ART treatments." On ovarian cancer it says something different: women "should be informed that there may be an increased risk of ovarian cancer associated with fertility treatment," with the overall risk likely small, and adds that it is difficult to separate that signal from underlying endometriosis, infertility itself, or never having given birth. For borderline ovarian tumors, the guideline again says risk may be increased and again attributes it plausibly to underlying infertility or nulliparity. For endometrial cancer, no conclusive evidence.

The two largest long-term cohorts explain that hedging. The Dutch OMEGA study (JAMA, 2016) followed 19,158 IVF-treated and 5,950 non-IVF-treated subfertile women for a median of 21 years and found no excess breast cancer, either against the comparison group (HR 1.01, 95% CI 0.86–1.19) or the general population (SIR 1.01, 95% CI 0.93–1.09). Its ovarian follow-up (Spaan et al., JNCI, 2021) tracked 30,625 ART-treated women for a median of 24 years. Against other subfertile women, invasive ovarian cancer risk was flat (HR 1.02, 95% CI 0.70–1.50). Against the general population it was elevated (SIR 1.43, 95% CI 1.18–1.71) — a difference the authors attribute to nulliparity rather than to treatment. Borderline tumors were raised on both comparisons, but with no dose-response across cycles, which the authors say means the finding "must be interpreted with caution."

The plain reading: there is no established causal link between ovarian stimulation and cancer, the strongest signals track the reasons women seek treatment rather than the treatment itself, and the residual uncertainty around borderline ovarian tumors is unresolved. "Not proven" is not the same sentence as "ruled out," and you deserve to know which one you are being given.

What is genuinely unknown

Three gaps are worth naming, because nobody can currently close them for you.

The cohorts are the wrong women. Every long-term safety dataset above studies subfertile patients treated between the 1980s and 2000, not healthy 33-year-olds electively banking eggs today. The drugs, protocols and trigger strategies have all changed since. The reassurance is real, but it is borrowed.

Menopause timing. The mechanistic argument that stimulation does not deplete your reserve is sound — the drugs rescue follicles from the cohort already recruited for that month, which would otherwise be lost. But there is no long-horizon study of elective egg freezers reaching menopause. We are not going to hand you a percentage for something that has not been measured.

Repeat cycles. Because most published safety data covers single cycles or donor programs, the cumulative risk profile of three or four retrievals is less well characterized than the risk of one — and older patients are precisely the ones most likely to need multiple cycles.

The advantages and disadvantages, weighed honestly

The advantage of egg freezing is that it preserves the chromosomal age of a batch of eggs while the rest of you keeps aging, and the obstetric evidence supporting that is good: ASRM's 2021 guideline reports no differences between vitrified and fresh oocytes in obstetric problems, gestational age at delivery, birth weight, Apgar scores, birth defects, NICU admission or perinatal mortality.

The disadvantages are the two weeks of side effects, a small but real procedural risk, a five-figure bill, and one thing the HFEA states more bluntly than most clinics ever will: "The major risk is that it won't work." Even under the favorable Goldman 2017 model, a 35-year-old with 20 mature eggs has a 90% modeled chance of at least one live birth — which the paper's own authors reduce to about 73% once the published frozen-versus-fresh gap is applied. Run your own figure through the success rate calculator first, because the size of the benefit is what makes these risks worth taking or not, and our fuller reckoning sits on is egg freezing worth it.

So is egg freezing safe?

For most healthy women the short-term safety record is good: serious complications sit well under 1%, the worst form of OHSS is largely a pregnancy-driven phenomenon that a freeze-all cycle avoids, and babies born from vitrified eggs show outcomes matching fresh. What you cannot buy is certainty about the next thirty years, or a guarantee that the eggs will deliver a child. A clinic that answers "is this safe?" with an unqualified yes is telling you less than the evidence does.